Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | VHL | P40337 | 1/20 | 0.38 |
| ▸ | ELOC | Q15369 | 1/20 | 0.38 |
| ▸ | ELOB | Q15370 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzyl Alcohol SCHEMBL27509109 | 0.88 | TSHR (0.64) | KMT2ATSHRENPP2TNFKDM4E | |
| SCHEMBL2154504 | 0.86 | KMT2A (0.47) | KMT2AENPP2TNFKDM4ETDP1 | |
| SCHEMBL5782186 | 0.80 | CA2 (0.52) | KMT2ATSHRENPP2TNFKDM4E | |
| SCHEMBL208982 | 0.79 | KDM4E (0.43) | KMT2ATSHRENPP2KDM4ETDP1 | |
| SCHEMBL448467 | 0.79 | MMP3 (0.57) | KMT2AKDM4EMMP3CA12CA1 | |
| SCHEMBL23137321 | 0.78 | MMP3 (0.50) | KMT2ATSHRENPP2TNFKDM4E | |
| SCHEMBL196175 | 0.78 | MMP3 (0.50) | KMT2ATSHRENPP2TNFKDM4E | |
| SCHEMBL8763328 | 0.78 | KMT2A (0.42) | KMT2ATSHRENPP2TNFKDM4E | |
| Methane SCHEMBL28234670 | 0.77 | MMP3 (0.55) | KMT2AKDM4EMMP3CA12CA1 | |
| SCHEMBL4374157 | 0.77 | ENPP2 (0.58) | KMT2ATSHRENPP2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| EP-4532484-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-04-09 | — | — | EP | disclosed |
| CN-119173509-A | ROCK inhibitors and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2023226965-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-11-30 | — | — | WO | disclosed |
| CN-111655700-B | Oxadiazolopyridine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors | 勃林格殷格翰国际有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-3746451-B1 | BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-07-12 | — | — | EP | disclosed |
| EP-3746451-B1 | BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023280177-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/β-CATENIN INTERACTION | 南通聚太生物科技有限公司 | 2023-01-12 | — | — | WO | disclosed |
| US-11254688-B2 | Benzyl-, (pyridin-3-yl)methyl -or (pyridin-4-yl)-methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-22 | — | — | US | disclosed |
| US-11254688-B2 | Benzyl-, (pyridin-3-yl)methyl -or (pyridin-4-yl)-methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-22 | — | — | US | disclosed |
| US-6335439-B1 | SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES BY REACTING OLIGONUCLEOTIDE OR NUCLEOSIDE WITH DIAMINOHALOPHOSPHINE TO PRODUCE PHOSPHORDIAMIDITE, THEN REACTING WITH ALCOHOL TO PRODUCE PHOSPHORAMIDITE | ISIS PHARMACEUTICALS, INC. | 2002-01-01 | — | — | US | disclosed |
| EP-1116720-A1 | PROCESSES FOR THE PREPARATION OF ISOCHROMANONES AND INTERMEDIATES FOR THE PREPARATION THEREOF | Showa Denko K.K. (JP) | 2001-07-18 | — | — | EP | disclosed |
| US-6160152-A | Process for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-6020475-A | Process for the synthesis of oligomeric compounds | ISIS PHARMEUTICALS, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1999064433-A1 | METHOD OF PREPARING PHOSPHORAMIDITES | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999040101-A1 | SYNTHETIC PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES, NUCLEOSIDE SYNTHONS USED THEREIN, AND OLIGONUCLEOTIDES PREPARED THEREBY | ISIS PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | disclosed |
| US-5374641-A | Thromboxane synthetase inhibitors, prostaglandin H2 antagonist , anticoagulants and antiallergens | TERUMO KABUSHIKI KAISHA (JP) | 1994-12-20 | — | — | US | disclosed |
| EP-0501876-A1 | N-(3-pyridylalkyl)sulfonamide derivative and pharmaceutical preparation containing thereof | TERUMO KABUSHIKI KAISHA (JP) | 1992-09-02 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, RHOA | KMT2A 3598/4885TSHR 3777/4885ENPP2 490/4885 |
| US-11254688-B2 | Benzyl-, (pyridin-3-yl)methyl -or (pyridin-4-yl)-methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors | MBOAT4, ADIPOR1, GIPR | KMT2A 1793/4885TSHR 55/4885ENPP2 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.